Advances in Cancer Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapy has become a cornerstone of treatment, particularly for hematopoietic malignancies, due to its specificity and effectiveness.
• Established immunotherapies include monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, and chimeric antigen receptor (CAR)-T cells.

Purpose of the Study:

• To review recent advancements in cancer immunotherapy, focusing on novel strategies for enhancing treatment efficacy and patient outcomes.
• To highlight emerging approaches for solid tumors and the integration of new technologies.

Main Methods:

• Review of recent literature on innovative cancer immunotherapy strategies.
• Analysis of novel CAR-T/NK cell designs and antibody-based therapies.
• Examination of the role of microbiota and neoantigen vaccination.

Main Results:

• Encapsulated fecal microbiota from healthy donors improved responses and reduced side effects with immune checkpoint inhibitors.
• New CAR-T/NK cell constructs with dual CARs or cytokine-inducing capabilities show promise for solid tumors.
• Gene-edited B cells producing antibodies and neoantigen-based vaccines combined with checkpoint inhibitors represent significant progress.

Conclusions:

• Recent innovations in cancer immunotherapy, including advanced cell therapies, microbiota modulation, and neoantigen vaccination, are expanding treatment options.
• These novel approaches offer improved efficacy and safety profiles, particularly for challenging solid tumors.